Pacira Biosciences, Inc.
Pacira BioSciences makes non-opioid pain treatments, best known for EXPAREL, a long-acting local anesthetic injected at the surgical site so patients recover from operations with less reliance on opioids. Its lineup also includes iovera°, a device that uses targeted cold to numb nerves. Founded in 2006 under the placeholder name Blue Acquisition Corp., the Tampa-based company later renamed itself Pacira and rebranded as Pacira BioSciences in 2019.
Granted 711.3K · Bought 8.3K
Granted 142.9K · Sold 36.2K
Granted 219.8K · Sold 19.4K
Granted 221.7K · Sold 45.2K
Granted 113.8K · Sold 8.7K
Granted 174.1K · Sold 62.1K
Granted 106.1K
Granted 71.2K · Sold 21.1K
Granted 37.1K · Sold 22.2K
Granted 29.2K · Sold 5.1K
Granted 23.4K · Sold 7.8K
Granted 8.0K · Sold 4.2K
Granted 29.3K · Sold 15.0K
Sold 2.3K
Granted 27.7K · Bought 1.0K · Sold 7.6K
Granted 58.0K · Sold 46.6K
Granted 20.7K · Bought 1.4K · Sold 1.5K
Granted 57.8K · Sold 54.7K
Granted 20.7K
Granted 29.6K · Sold 21.2K
Granted 46.9K · Sold 154.3K
Granted 17.8K · Bought 2.0K
Granted 7.0K · Sold 7.0K
Granted 17.8K · Bought 4.9K · Sold 4.9K
Granted 17.8K
Granted 1.2K
Granted 32.5K · Sold 35.8K
Granted 15.2K · Sold 9.0K
Granted 11.4K · Sold 2.4K
Granted 6.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lee Frank D.Chief Executive Officer, Director · 7 transactions | — | 660.8K | 711.3K | 8.3K | — |
| Stack David MCEO and Chairman, Director · 14 transactions | +55.1% | 302.7Kas of Jun 2023 | 142.9K | — | 36.2K |
| Slonin JonathanChief Medical Officer · 27 transactions | +730.8% | 218.9K | 219.8K | — | 19.4K |
| Williams KristenChief Administrative Officer · 12 transactions | — | 167.1K | 221.7K | — | 45.2K |
| Gaugler DarylChief Operating Officer · 17 transactions | — | 115.4Kas of Dec 2024 | 113.8K | — | 8.7K |
| Cross ShawnChief Financial Officer · 16 transactions | — | 105.3K | 174.1K | — | 62.1K |
| Teehan BrendanChief Commercial Officer · 4 transactions | — | 100.9K | 106.1K | — | — |
| Riker LaurenSenior Vice President, Finance · 15 transactions | — | 62.3K | 71.2K | — | 21.1K |
| Winston RoyChief Medical Officer · 17 transactions | +43.8% | 52.4Kas of Aug 2023 | 37.1K | — | 22.2K |
| Reinhart Charles A. IIIChief Financial Officer · 7 transactions | +68.4% | 51.9Kas of Jun 2024 | 29.2K | — | 5.1K |
| Laranjeira Charles AnthonyChief Technical Officer · 8 transactions | +62.6% | 41.8Kas of Jun 2022 | 23.4K | — | 7.8K |
| McLoughlin DennisChief Customer Officer · 4 transactions | +13.6% | 38.1Kas of Jun 2023 | 8.0K | — | 4.2K |
| Kronenfeld Mark A.Director · 6 transactions | +85.6% | 31.1Kas of Jun 2025 | 29.3K | — | 15.0K |
| Ellis Ronald J. Jr.Chief Strategy Officer · 2 transactions | — | 30.9Kas of Jun 2023 | — | — | 2.3K |
| Brege LauraDirector · 9 transactions | +235.2% | 30.1K | 27.7K | 1.0K | 7.6K |
| Reinhardt MaxPresident, Rest of World · 14 transactions | +67% | 29.2Kas of Jun 2023 | 58.0K | — | 46.6K |
| Froimson MarkDirector · 9 transactions | +320.8% | 26.5K | 20.7K | 1.4K | 1.5K |
| Williams Kristen MarieChief Administrative Officer · 30 transactions | +9.8% | 25.4Kas of Jun 2023 | 57.8K | — | 54.7K |
| Christie ChristopherDirector · 5 transactions | +891.4% | 23.1K | 20.7K | — | — |
| Riker Lauren BullaroSenior Vice President, Finance · 15 transactions | +71.3% | 22.7Kas of Jul 2023 | 29.6K | — | 21.2K |
| Pace Gary WDirector · 14 transactions | -82.9% | 22.1Kas of Mar 2024 | 46.9K | — | 154.3K |
| Yang Michael J.Director · 4 transactions | — | 19.8K | 17.8K | 2.0K | — |
| Longenecker John P PHDDirector · 2 transactions | 0% | 18.8Kas of Mar 2022 | 7.0K | — | 7.0K |
| Bigal MarceloDirector · 6 transactions | — | 17.8K | 17.8K | 4.9K | 4.9K |
| Young AlethiaDirector · 3 transactions | — | 17.8K | 17.8K | — | — |
| Greenstreet YvonneDirector · 1 transaction | +9.6% | 13.2Kas of Jun 2022 | 1.2K | — | — |
| Molloy AnthonyChief Lgl & Compliance Officer · 17 transactions | — | 12.9Kas of Jun 2023 | 32.5K | — | 35.8K |
| Hastings Paul JDirector · 8 transactions | +94.2% | 12.7Kas of Jun 2024 | 15.2K | — | 9.0K |
| Ceesay AbrahamDirector · 3 transactions | — | 9.0K | 11.4K | — | 2.4K |
| Hirawat SamitDirector · 1 transaction | — | 6.4K | 6.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -576.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.